After a five-year hiatus, the Prostate Cancer Survivors Celebration Breakfast is making a comeback at the Sheraton Seattle Hotel on December 9, 2010. The breakfast, the foremost fundraising event in the Northwest region dedicated to raising money and awareness for prostate cancer research, has become a symbol of strength, hope and community for prostate cancer survivors and their families. Volunteer leaders have set a goal to raise $1 million for the Institute for Prostate Cancer Research (IPCR), a collaboration between UW Medicine and Fred Hutchinson Cancer Research Center.
Event chair and prostate cancer survivor Steve Fleischmann has been the driving force behind this event since its inception. “I am very passionate about this breakfast, and I can’t thank everyone enough who has supported this event over the years and will continue to support the breakfast this December, “Fleischmann said. “Our commitment to finding a cure for prostate cancer right here in Seattle is so vitally important. The money raised for this breakfast will make a huge difference in being able to continue all the necessary research.”
Mitchell H. Gold, M.D., a resident alumnus of the UW School of Medicine and the president and chief executive officer of Seattle-based Dendreon Corp., is the keynote speaker at this year’s Survivors Celebration Breakfast. Dendreon is responsible for the creation of Provenge, a new therapy to treat advanced prostate cancer. “With the recent FDA approval of Provenge, we have made an important advancement in the field of prostate cancer research to benefit patients,” said Gold, who also did his residency in urology at the University of Washington. “More progress needs to be made, and that can only be fueled by funding for more research. UW Medicine and Fred Hutchinson Cancer Research Center are pioneering some of the most innovative research in the field of prostate cancer, and the Survivors Celebration breakfast is our community's primary opportunity to foster the important work conducted by the IPCR to help men with prostate cancer live longer and better lives.”
The IPCR brings together more than 40 scientists and clinicians in multiple disciplines to understand the causes of prostate cancer and its progression, develop new prevention strategies, devise innovative diagnostics, and improve survival and quality of life. Together, these researchers already have identified and/or assembled up to 80 percent of the genes expressed in prostate cancer, developed one of the largest serum and tissue banks in the world, undertaken some of the most advanced studies of bone biology and skeletal metastases, assembled information and genotypes for more than 300 families with hereditary prostate cancer, and developed many new therapeutic strategies. With the support secured by the breakfast, the IPCR will be able to make further breakthroughs in understanding and treating prostate cancer.
To learn more about the IPCR and the Prostate Cancer Survivors Breakfast on Thursday, December 9, 7:30–9:00a.m., at the Sheraton Seattle, or to purchase tickets to the event ($250 / person, $2,500 / table of 10), visit www.supportuwmedicine.org/pc-survivors or call: (206) 543-7873. Visit www.uwmedicine.org to learn more about UW Medicine and www.fhcrc.org to learn more about Fred Hutchinson Cancer Research Center.